

[Sign In](#) | [Register](#)[Home](#) | [News](#) | [Get involved](#) | [About NICE](#)

[Home](#) > [About NICE](#) > [How we work](#) > [Patient access schemes liaison unit \(PASLU\)](#) >  
List of technologies with approved Patient Access Schemes, recommended by NICE for use in the NHS.

## List of technologies with approved Patient Access Schemes, recommended by NICE for use in the NHS.

TA Ref	Treatment	Indication	Company	Type
TA185	Trabectedin (Yondelis)	Advanced soft tissue sarcoma	PharmaMar	Dose cap
TA155	Ranibizumab (Lucentis)	Macular degeneration (Acute wet AMD)	Novartis	Simple discount
TA171	Lenalidomide (Revlimid)	Multiple myeloma	Celgene	Dose cap
TA162	Erlotinib (Tarceva)	Non small cell lung cancer	Roche	Simple discount
TA129	Bortezomib (Velcade)	Multiple myeloma	JC	Response scheme
TA180	Ustekinumab (Stelera)	Moderate to severe psoriasis	J&J / JC	Free stock
TA179	Sunitinib (Sutent)	Gastrointestinal stromal tumour	Pfizer	Free stock
TA176	Cetuximab (Erbix)	Metastatic colorectal cancer (first Line)	Merck S.	Rebate
TA169	Sunitinib (Sutent)	Renal cell carcinoma	Pfizer	Free stock
TA186	Certolizumab pegol (Cimzia)	Rheumatoid arthritis	UCB	Free initial stock
TA192	Gefitinib (Iressa)	Non small cell lung cancer	Astra Zeneca	Single fixed price

TA215	Pazopanib (Votrient)	Advanced renal cell carcinoma	GSK	Discount+ poss rebate
TA218	Azacitidine (Vidaza)	Myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia	Celgene	Simple discount
TA220	Golimumab (Simponi)	Psoriatic arthritis	Merck Sharp & Dohme	Free stock
TA221	Romiplostim (Nplate)	Chronic idiopathic (immune) thrombocytopenic purpura	Amgen	Simple discount
TA225	Golimumab (Simponi)	Rheumatoid arthritis	Merck Sharp & Dohme	Free stock
TA233	Golimumab (Simponi)	Ankylosing spondylitis	Merck Sharp & Dohme	Free stock
TA235	Mifamurtide (Mepact)	High grade resectable non-metastatic osteosarcoma	Takeda	Simple discount
TA238	Tocilizumab (RoActemra)	Systemic juvenile idiopathic arthritis	Roche	Simple discount
TA241	Nilotinib (Tasigna)	Imatinib-resistant chronic myeloid leukaemia	Novartis	Simple discount
TA247	Tocilizumab (RoActemra)	Rheumatoid arthritis	Roche	Simple discount
TA251	Nilotinib (Tasigna)	First-line treatment of chronic myeloid leukaemia	Novartis	Simple discount
TA254	Fingolimod (Gilenya)	Highly active relapsing-remitting multiple sclerosis	Novartis	Simple discount
TA258	Erlotinib (Tarceva)	First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer	Roche	Simple discount
TA259	Abiraterone acetate (Zytiga)	Castration-resistant metastatic prostate cancer previously treated with a docetaxel containing regimen	Janssen-Cilag	Simple discount

Explore NICE	Evidence Search
NICE Community	

TA265	Denosumab (Xgeva)	Skeletal related events in adults with bone metastases from solid tumours	Amgen	Simple discount
TA268	Ipilimumab (Yervoy)	Advanced melanoma, 2 <sup>nd</sup> Line	Bristol-Myers Squibb	Simple discount
TA269	Vemurafenib (Zelboraf)	Metastatic mutation positive melanoma	Roche	Simple discount
TA274	Ranibizumab (Lucentis)	Diabetic macular odema	Novartis	Simple discount
TA276	Colistimethate (Colobreathe)	Pseudomonas aeruginosa for adults and children over 6 with cystic fibrosis	Forest Laboratories UK	Simple discount
TA276	Tobramycin (TOBI Podhaler)	Pseudomonas aeruginosa for adults and children over 6 with cystic fibrosis	Novartis	Simple discount
TA278	Omalizumab (Xolair)	Severe persistent asthma	Novartis	Simple discount
TA280	Abatacept (Orencia)	Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis	Bristol-Myers Squibb	Simple discount
TA282	Pirfenidone (Esbriet)	Mild to moderate idiopathic pulmonary fibrosis	Intermune	Simple discount

This page was last updated: 14 May 2013

#### About NICE

Who we are, What we do, How we work

#### Get Involved

Current Consultations, Join a working group

#### Scientific Advice Consultancy

Advice to pharmaceutical companies

#### Quality Initiatives

Clinical commissioning group outcomes indicator set, Quality and Outcomes Framework, NICE fellows and scholars

#### NICE International

NICE International Advisory group, International projects

#### NICE accreditation

What's new in accreditation, accreditation decisions

#### Cost saving support

#### NICE Guidance

Find Guidance, Clinical Guidelines, Diagnostics, Interventional Procedures, Medical Technologies, Public Health, Quality Standards, Social care, Technology Appraisals

#### NICE Quality Standards

Published quality standards, Quality standards in development, Social care quality standards

#### Research and development

#### Research recommendations

Search, Latest recommendations

**Patients and the public**  
Search guidance, Treatment and care,  
Join a working group

**Other publications**  
Special reports and HDA publications

**Social care**

**Support for General Practice**  
Resources for GPs, NICE  
Commissioning resources

**Commissioning guides**  
Commissioning guides for  
Cardiovascular, Central nervous  
system, Digestive system

**Putting guidance into practice**  
Benefits, Implementation tools, How to  
guides, Assessment tools, Help  
implement NICE Guidance ...

**Education and learning**  
Education, Strategy, Online tools

**Shared learning**  
Shared learning implementation  
guidance

**Notify NICE**  
New and reviewed Interventional  
procedures

**Medicines and prescribing support**  
Evidence summaries: new medicines,  
Events, Alerts

**News and press**  
NICE press office, News and features,  
Press releases, Latest News